• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抑瘤素 M 信号通路促进癌性骨骼肌消耗。

Oncostatin M signaling drives cancer-associated skeletal muscle wasting.

机构信息

Department of Molecular Biology and Genetics, Koc University, Istanbul 34450, Turkiye.

Department of Molecular Biology and Genetics, Koc University, Istanbul 34450, Turkiye.

出版信息

Cell Rep Med. 2024 Apr 16;5(4):101498. doi: 10.1016/j.xcrm.2024.101498. Epub 2024 Apr 4.

DOI:10.1016/j.xcrm.2024.101498
PMID:38569555
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11031427/
Abstract

Progressive weakness and muscle loss are associated with multiple chronic conditions, including muscular dystrophy and cancer. Cancer-associated cachexia, characterized by dramatic weight loss and fatigue, leads to reduced quality of life and poor survival. Inflammatory cytokines have been implicated in muscle atrophy; however, available anticytokine therapies failed to prevent muscle wasting in cancer patients. Here, we show that oncostatin M (OSM) is a potent inducer of muscle atrophy. OSM triggers cellular atrophy in primary myotubes using the JAK/STAT3 pathway. Identification of OSM targets by RNA sequencing reveals the induction of various muscle atrophy-related genes, including Atrogin1. OSM overexpression in mice causes muscle wasting, whereas muscle-specific deletion of the OSM receptor (OSMR) and the neutralization of circulating OSM preserves muscle mass and function in tumor-bearing mice. Our results indicate that activated OSM/OSMR signaling drives muscle atrophy, and the therapeutic targeting of this pathway may be useful in preventing muscle wasting.

摘要

进行性无力和肌肉萎缩与多种慢性疾病有关,包括肌肉营养不良和癌症。癌症相关性恶病质的特征是体重明显下降和疲劳,导致生活质量下降和预后不良。炎症细胞因子与肌肉萎缩有关;然而,现有的抗细胞因子疗法未能预防癌症患者的肌肉消耗。在这里,我们表明,肿瘤坏死因子 M(OSM)是肌肉萎缩的一个强有力的诱导剂。OSM 通过 JAK/STAT3 途径触发原代肌管的细胞萎缩。通过 RNA 测序鉴定 OSM 靶标,揭示了各种与肌肉萎缩相关基因的诱导,包括 Atrogin1。在小鼠中过表达 OSM 会导致肌肉消耗,而肌肉特异性敲除 OSM 受体(OSMR)和中和循环 OSM 可在荷瘤小鼠中保留肌肉质量和功能。我们的结果表明,激活的 OSM/OSMR 信号驱动肌肉萎缩,靶向该途径的治疗可能有助于预防肌肉消耗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09c6/11031427/6cf22b86377c/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09c6/11031427/94101e88387f/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09c6/11031427/f7ad9b32fd47/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09c6/11031427/7aa36c5fe25a/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09c6/11031427/22d82bc57285/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09c6/11031427/c440aae8b9cf/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09c6/11031427/6cf22b86377c/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09c6/11031427/94101e88387f/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09c6/11031427/f7ad9b32fd47/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09c6/11031427/7aa36c5fe25a/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09c6/11031427/22d82bc57285/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09c6/11031427/c440aae8b9cf/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09c6/11031427/6cf22b86377c/gr5.jpg

相似文献

1
Oncostatin M signaling drives cancer-associated skeletal muscle wasting.抑瘤素 M 信号通路促进癌性骨骼肌消耗。
Cell Rep Med. 2024 Apr 16;5(4):101498. doi: 10.1016/j.xcrm.2024.101498. Epub 2024 Apr 4.
2
EDA2R-NIK signalling promotes muscle atrophy linked to cancer cachexia.EDA2R-NIK 信号促进与癌症恶病质相关的肌肉萎缩。
Nature. 2023 May;617(7962):827-834. doi: 10.1038/s41586-023-06047-y. Epub 2023 May 10.
3
Exogenous Oncostatin M induces Cardiac Dysfunction, Musculoskeletal Atrophy, and Fibrosis.外源性肿瘤坏死因子样弱诱导因子诱导心脏功能障碍、肌肉骨骼萎缩和纤维化。
Cytokine. 2022 Nov;159:155972. doi: 10.1016/j.cyto.2022.155972. Epub 2022 Aug 30.
4
A Key Role for Leukemia Inhibitory Factor in C26 Cancer Cachexia.白血病抑制因子在C26癌症恶病质中的关键作用。
J Biol Chem. 2015 Aug 7;290(32):19976-86. doi: 10.1074/jbc.M115.638411. Epub 2015 Jun 19.
5
Anti-oncostatin M antibody inhibits the pro-malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma.抗瘤抑素 M 抗体抑制鳞状细胞癌中瘤抑素 M 受体过表达的促恶性作用。
J Pathol. 2018 Mar;244(3):283-295. doi: 10.1002/path.5010. Epub 2018 Jan 9.
6
Oncostatin M induces C2C12 myotube atrophy by modulating muscle differentiation and degradation.抑瘤素 M 通过调节肌肉分化和降解诱导 C2C12 肌管萎缩。
Biochem Biophys Res Commun. 2019 Aug 27;516(3):951-956. doi: 10.1016/j.bbrc.2019.06.143. Epub 2019 Jul 2.
7
EDA2R-NIK signaling in cancer cachexia.EDA2R-NIK 信号通路在癌症恶病质中的作用。
Curr Opin Support Palliat Care. 2024 Sep 1;18(3):126-131. doi: 10.1097/SPC.0000000000000705. Epub 2024 May 27.
8
Oncostatin M: Dual Regulator of the Skeletal and Hematopoietic Systems.抑瘤素M:骨骼和造血系统的双重调节因子
Curr Osteoporos Rep. 2024 Feb;22(1):80-95. doi: 10.1007/s11914-023-00837-z. Epub 2024 Jan 10.
9
Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.丙戊酸通过抑制 C/EBPβ 调节的肌萎缩蛋白 1 表达来减轻癌症恶病质引起的骨骼肌消耗。
Am J Physiol Cell Physiol. 2016 Jul 1;311(1):C101-15. doi: 10.1152/ajpcell.00344.2015. Epub 2016 Apr 27.
10
Oncostatin M receptor, positively regulated by SP1, promotes gastric cancer growth and metastasis upon treatment with Oncostatin M.受 SP1 正向调控的抑瘤素 M 受体促进了抑瘤素 M 治疗后的胃癌生长和转移。
Gastric Cancer. 2019 Sep;22(5):955-966. doi: 10.1007/s10120-019-00934-y. Epub 2019 Feb 18.

引用本文的文献

1
Exercise-mediated IL-6 downstream effects modulate brain pathology-can exercise training protocols influence the downstream effects?运动介导的白细胞介素-6下游效应调节脑病理学——运动训练方案能否影响下游效应?
Front Neurol. 2025 Aug 6;16:1639427. doi: 10.3389/fneur.2025.1639427. eCollection 2025.
2
Cancer therapy and cachexia.癌症治疗与恶病质。
J Clin Invest. 2025 Aug 1;135(15). doi: 10.1172/JCI191934.
3
Unraveling the role of STAT3 in Cancer Cachexia: pathogenic mechanisms and therapeutic opportunities.解析信号转导和转录激活因子3(STAT3)在癌症恶病质中的作用:致病机制与治疗机遇

本文引用的文献

1
Muscle wasting: emerging pathways and potential drug targets.肌肉减少症:新出现的途径和潜在的药物靶点。
Trends Pharmacol Sci. 2023 Oct;44(10):705-718. doi: 10.1016/j.tips.2023.07.006. Epub 2023 Aug 17.
2
EDA2R-NIK signalling promotes muscle atrophy linked to cancer cachexia.EDA2R-NIK 信号促进与癌症恶病质相关的肌肉萎缩。
Nature. 2023 May;617(7962):827-834. doi: 10.1038/s41586-023-06047-y. Epub 2023 May 10.
3
Cachexia: A systemic consequence of progressive, unresolved disease.恶病质:进行性、未解决疾病的全身性后果。
Front Endocrinol (Lausanne). 2025 Jul 9;16:1608612. doi: 10.3389/fendo.2025.1608612. eCollection 2025.
4
The canonical ER stress IRE1α/XBP1 pathway mediates skeletal muscle wasting during pancreatic cancer cachexia.经典的内质网应激IRE1α/XBP1信号通路介导胰腺癌恶病质期间的骨骼肌萎缩。
bioRxiv. 2025 Aug 4:2025.05.05.652304. doi: 10.1101/2025.05.05.652304.
5
The TWEAK/Fn14 signaling mediates skeletal muscle wasting during cancer cachexia.TWEAK/Fn14信号传导在癌症恶病质期间介导骨骼肌萎缩。
iScience. 2025 May 30;28(7):112714. doi: 10.1016/j.isci.2025.112714. eCollection 2025 Jul 18.
6
Exploring the Role of Inflammation and Metabolites in Bell's Palsy and Potential Treatment Strategies.探索炎症和代谢产物在贝尔面瘫中的作用及潜在治疗策略。
Biomedicines. 2025 Apr 13;13(4):957. doi: 10.3390/biomedicines13040957.
7
Transcriptional analysis of cancer cachexia: conserved and unique features across preclinical models and biological sex.癌症恶病质的转录组学分析:临床前模型和生物性别之间的保守和独特特征。
Am J Physiol Cell Physiol. 2024 Dec 1;327(6):C1514-C1531. doi: 10.1152/ajpcell.00647.2024. Epub 2024 Oct 28.
8
Tumour-induced alterations in single-nucleus transcriptome of atrophying muscles indicate enhanced protein degradation and reduced oxidative metabolism.肿瘤诱导的萎缩肌肉单细胞核转录组变化表明蛋白质降解增强和氧化代谢降低。
J Cachexia Sarcopenia Muscle. 2024 Oct;15(5):1898-1914. doi: 10.1002/jcsm.13540. Epub 2024 Jul 13.
Cell. 2023 Apr 27;186(9):1824-1845. doi: 10.1016/j.cell.2023.03.028.
4
Cancer-associated cachexia - understanding the tumour macroenvironment and microenvironment to improve management.癌症相关性恶病质——了解肿瘤的宏观环境和微观环境以改善管理。
Nat Rev Clin Oncol. 2023 Apr;20(4):250-264. doi: 10.1038/s41571-023-00734-5. Epub 2023 Feb 20.
5
SERPINA3: Stimulator or Inhibitor of Pathological Changes.丝氨酸蛋白酶抑制剂A3:病理变化的刺激物还是抑制剂?
Biomedicines. 2023 Jan 7;11(1):156. doi: 10.3390/biomedicines11010156.
6
Exogenous Oncostatin M induces Cardiac Dysfunction, Musculoskeletal Atrophy, and Fibrosis.外源性肿瘤坏死因子样弱诱导因子诱导心脏功能障碍、肌肉骨骼萎缩和纤维化。
Cytokine. 2022 Nov;159:155972. doi: 10.1016/j.cyto.2022.155972. Epub 2022 Aug 30.
7
Downregulation of miR-29c promotes muscle wasting by modulating the activity of leukemia inhibitory factor in lung cancer cachexia.miR-29c的下调通过调节肺癌恶病质中白血病抑制因子的活性促进肌肉萎缩。
Cancer Cell Int. 2021 Nov 27;21(1):627. doi: 10.1186/s12935-021-02332-w.
8
Metallothionein 1: A New Spotlight on Inflammatory Diseases.金属硫蛋白 1:炎症性疾病的新焦点。
Front Immunol. 2021 Nov 5;12:739918. doi: 10.3389/fimmu.2021.739918. eCollection 2021.
9
AMP deamination is sufficient to replicate an atrophy-like metabolic phenotype in skeletal muscle.AMP脱氨基作用足以在骨骼肌中复制类似萎缩的代谢表型。
Metabolism. 2021 Oct;123:154864. doi: 10.1016/j.metabol.2021.154864. Epub 2021 Aug 13.
10
Anti-inflammatory nanoparticles significantly improve muscle function in a murine model of advanced muscular dystrophy.抗炎纳米颗粒显著改善晚期肌肉萎缩症小鼠模型的肌肉功能。
Sci Adv. 2021 Jun 23;7(26). doi: 10.1126/sciadv.abh3693. Print 2021 Jun.